U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Dherbs Health Emporium Inc. - 475507 - 07/03/2018
  1. Warning Letters

CLOSEOUT LETTER

Dherbs Health Emporium Inc. MARCS-CMS 475507 —

Recipient:
Dherbs Health Emporium Inc.

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

 
 
1431 Harbor Bay Parkway
Alameda, CA 94502-7070  

July 03, 2018

Mr. Ahman Dolphin, CEO
Dherbs Health Emporium Inc.
2734 Fletcher Drive
Los Angeles, CA 90039

Dear Mr. Ahman Dolphin:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (CMS # 475507), dated December 10, 2015. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Sergio Chavez, Director of Compliance
Office Human and Animal Foods
Division West 5
 

Back to Top